Papers
4
Total Citations
105
H-Index
4
About
Rosie Clow is a clinical researcher whose work centers on improving functional outcomes for men undergoing robot-assisted radical prostatectomy (RARP) for localized prostate cancer. Her major contribution is leading the NeuroSAFE PROOF trial, a landmark multicentre, patient-blinded, randomized controlled phase 3 study that rigorously evaluated the NeuroSAFE technique—a standardized intraoperative frozen section analysis designed to preserve neurovascular bundles while ensuring oncological safety. Clow’s research demonstrated that NeuroSAFE-guided RARP significantly improves postoperative erectile function and early urinary continence recovery compared to standard surgery, directly addressing two of the most debilitating side effects of prostate cancer treatment. Her work, cited over 100 times collectively, includes the trial’s feasibility study, protocol, and definitive phase 3 results, which have shaped surgical practice and quality-of-life priorities in urologic oncology. Clow’s dedication to evidence-based surgical innovation has made her a key voice in advancing nerve-sparing techniques, offering men with prostate cancer a better chance at maintaining sexual and urinary function after curative treatment.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4